Regulation of Biotechnology Technology Transfer Agreements in China

1. Introduction

Biotechnology technology transfer agreements in China govern the transfer, licensing, development, and commercial exploitation of technologies such as genetic engineering, vaccines, gene therapy, pharmaceutical biotechnology, industrial microorganisms, bio-manufacturing processes, and diagnostic platforms. These agreements may involve Chinese universities, research institutions, biotechnology companies, foreign investors, pharmaceutical manufacturers, and multinational corporations.

The principal legal challenge is that biotechnology transfers are not governed by a single statute. Instead, they are regulated through a combination of the Civil Code, Patent Law, Foreign Investment Law, Technology Import and Export Administration Regulations, Biosecurity Law, Human Genetic Resources Regulation, and applicable intellectual property and competition rules.

The legal framework seeks to balance contractual freedom and commercial innovation with technology security, protection of intellectual property, public health, and national interests. A technology transfer agreement that is commercially valid may nevertheless require additional regulatory approvals, filings, or compliance measures before the technology can lawfully be imported, exported, researched, or commercialised.

2. Principal Legal Framework

A. Civil Code of the People's Republic of China

The Civil Code, effective from 1 January 2021, provides the general contractual foundation for biotechnology technology transfer.

Its technology-contract provisions, particularly Articles 843–887, address technology development, transfer, licensing, consultation, and service arrangements. Articles 862 onward distinguish technology transfer contracts from technology licensing contracts.

The main obligations generally include:

The transferor must provide the technology, technical documentation, and agreed assistance.

The transferee must pay royalties or other agreed consideration and comply with contractual restrictions.

The parties must define ownership of improvements, confidential know-how, and jointly developed inventions.

Contractual provisions must comply with mandatory Chinese law and public policy.

A biotechnology contract should specify whether the transaction concerns a patent assignment, a patent licence, transfer of technical know-how, a research collaboration, or a combination of these arrangements. The legal consequences differ according to the structure selected.

B. Patent Law

China's Patent Law protects qualifying biotechnology inventions, including certain genetic engineering methods, biological materials, microorganisms, pharmaceutical compositions, and manufacturing processes.

However, patentability is subject to statutory exclusions and requirements such as novelty, inventiveness, and practical applicability. Scientific discoveries and certain methods of diagnosis or treatment of diseases are not patentable as such.

A transfer agreement should identify the relevant patent numbers, pending applications, jurisdictions, ownership records, remaining protection periods, and any existing licences or security interests.

Patent assignment and licensing must also be distinguished. An assignment transfers ownership, whereas a licence grants specified exploitation rights without necessarily transferring title. Patent assignments generally require registration to take effect under Chinese patent law.

C. Technology Import and Export Administration Regulations

The Regulations on Technology Import and Export Administration apply when technology moves into or out of China through trade, investment, or economic and technical cooperation. They cover patent assignments, patent licences, technical secrets, and technical services.

WIPO

+1

The principal distinction is between:

Prohibited technology: Transfer is not permitted.

Restricted technology: Transfer requires the applicable government licence.

Freely transferable technology: Generally subject to contract registration rather than prior licensing.

This distinction is particularly important for biotechnology exports involving genetic engineering, specialised biological manufacturing, or other technologies potentially covered by China's technology export control catalogue.

The legal position changed significantly in 2019, when China amended the Regulations to remove several provisions that had imposed mandatory contractual conditions on foreign technology importers and suppliers. Therefore, older legal commentary should not be treated as a complete statement of the current framework.

D. Foreign Investment Law

Article 22 of the Foreign Investment Law protects intellectual property rights and states that technology cooperation connected with foreign investment should follow voluntary principles and commercial rules, with contractual terms negotiated on an equal basis. It also prohibits administrative authorities and their personnel from forcing technology transfers through administrative means.

web.patent-judicial-guide.wji.prd.web1.wipo.int

+1

For a foreign biotechnology company establishing a Chinese subsidiary, joint venture, or research partnership, this provision is important because technology contributions should be based on negotiated commercial arrangements rather than compulsory administrative demands.

3. Biotechnology-Specific Regulatory Considerations

Technology transfer agreements may trigger additional legal requirements depending on the technology and materials involved.

Human genetic resources: Transfers involving Chinese human genetic resources, associated information, or international collaborative research may be subject to the Human Genetic Resources framework. Separate rules govern international cooperation, collection, preservation, and provision or external access to relevant resources and information.

Biosecurity: The Biosecurity Law may apply where transferred technology involves pathogenic microorganisms, biotechnology research with biosecurity implications, or controlled biological materials.

Data protection: Transfers involving personal information or important data may engage the Personal Information Protection Law, Data Security Law, and applicable cross-border data rules.

Competition law: Exclusivity, restrictive licensing, tying arrangements, market allocation, and other clauses must be assessed under China's Anti-Monopoly Law and applicable technology-contract rules.

Consequently, an agreement to license a gene-editing platform may raise different regulatory questions from an agreement transferring a vaccine manufacturing process or a collection of engineered microorganisms.

4. Important Case Laws

A. Ai Mou Diagnostics Co., Ltd. v. Wuhan Bo Mou Biotechnology Co., Ltd. (2023) ZGFZMZ No. 2913

The Supreme People's Court delivered its judgment on 30 December 2024 in this biotechnology-related trade secret dispute. The case concerned alleged unfair competition and misappropriation of technical secrets involving a biotechnology company and a former employee.

WIPO

Legal significance: The case illustrates the importance of confidentiality agreements, evidence of trade secret protection, employee obligations, and liability for misappropriating proprietary technical information. Biotechnology companies should maintain documented access controls and clearly identify confidential laboratory protocols, diagnostic methods, and technical data.

B. Tianjin Greenpine Pharma Co. v. Huabei Pharmaceutical Hebei Huamin Pharmaceutical Co.

In this patent ownership dispute, the Supreme People's Court considered allegations that technical secrets had been misappropriated and incorporated into patented technology. The Court examined whether the confidential technical information appeared in the patent documents and whether it formed part of the patented technical solution.

Other patent-related civil cases

Legal significance: A biotechnology transferor should verify the origin and ownership of the technology before licensing or assigning it. A transferee should conduct due diligence to ensure that transferred inventions do not incorporate another party's misappropriated technical secrets.

C. Supreme People's Court Interpretation on Technology Contract Disputes

The Supreme People's Court's Interpretation on Several Issues concerning the Application of Laws in the Trial of Cases involving Technology Contract Disputes, amended in 2020 and effective in its amended form from 1 January 2021, provides an important judicial framework for technology-transfer disputes.

WIPO

+1

The interpretation addresses unlawful technological monopolisation, ownership of improvements, fraudulent technology-development contracts, and disputes involving confidential technical information.

Legal significance: A contract clause that unfairly prevents the licensee from improving the technology, requires uncompensated transfer of improvements, or imposes unreasonable restrictions on competing technologies may be challenged as unlawful technological monopolisation.

D. WTO Dispute: China — Certain Measures on the Transfer of Technology, DS549

The European Union challenged Chinese measures concerning technology transfer under the World Trade Organization dispute-settlement system. The dispute raised concerns about restrictions on foreign intellectual property holders and their ability to negotiate technology-transfer terms.

Trade and Economic Security

Legal significance: This was an international trade dispute, not a domestic Chinese court judgment. It provides important context for understanding the evolution of China's technology-transfer regime and the 2019 amendments removing several mandatory contractual provisions.

5. Essential Contractual Safeguards

A biotechnology technology-transfer agreement should expressly address:

Ownership and scope: Identify patents, know-how, biological materials, technical documentation, and licensed fields of use.

Improvements: Specify ownership, licensing rights, and compensation for subsequent inventions.

Confidentiality: Define protected information, access restrictions, permitted disclosures, and survival periods.

Regulatory compliance: Allocate responsibility for technology import/export licences, genetic-resource approvals, biosafety, and data transfers.

Warranties and indemnities: Address ownership, authority to license, technical performance, and third-party infringement claims.

Dispute resolution: Specify governing law, jurisdiction or arbitration, remedies, and procedures for protecting confidential evidence.

6. Conclusion

China regulates biotechnology technology-transfer agreements through an integrated framework of contract law, patent protection, technology import/export controls, foreign investment rules, biosecurity, data governance, and competition law. The most significant practical risks concern ownership of technical secrets, restrictions on improvements, cross-border regulatory compliance, and contractual provisions that unlawfully restrict competition.

The cited cases demonstrate that clear ownership records, enforceable confidentiality protections, carefully drafted improvement clauses, and regulatory due diligence are central to lawful biotechnology commercialisation in China. The precise obligations depend on the technology, the parties' locations, the transaction structure, and the applicable regulatory classifications.